BRAF/MEK Inhibition in NSCLC: Mechanisms of Resistance and How to Overcome It

Investigators discuss inhibition of BRAF and its downstream effector MEK which constitutes a therapeutic strategy for a subset of patients with NSCLC and is associated with clinical benefit.
[Clinical and Translational Oncology]

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News